WeVote
Log In

Bill

Bill

A 4923

Creates grant program in DOH to increase early detection of and intervention for uterine fibroids; appropriates $5 million.

2026-2027 Regular Session

NJ DOH grants $5 million to boost early detection, screening, and timely intervention for uterine fibroids across awareness, provider training, and access programs.

Introduced, Referred to Assembly Health Committee
0
WeVote Research Nonpartisan
Bill Summary · A 4923

Summary of New Jersey Assembly Bill A-4923 (Session 222)

Title

Creates a grant program in the Department of Health (DOH) to increase early detection of and intervention for uterine fibroids; appropriates $5 million.

Primary Purpose and Intent

  • Establish a dedicated grant program within the New Jersey Department of Health to improve the early identification, screening, diagnosis, and timely intervention for uterine fibroids.
  • Allocate state funding to support initiatives aimed at reducing delays in diagnosis and expanding access to appropriate treatments and management options for individuals affected by uterine fibroids.

Key Provisions and Changes

  • Grant Program Establishment

    • Creates a grant program within DOH focused on uterine fibroids.
    • Aims to support activities that enhance early detection, diagnosis, education, and intervention strategies.

  • Funding and Appropriation

    • Authorizes a total appropriation of $5,000,000 to be allocated to the DOH grant program.
    • Details regarding grant duration, annual allocation, or specific distribution methodology are not provided in the summary; such details would typically be established in implementing regulations or by the DOH in conjunction with the bill’s provisions.

  • Eligible Activities (likely scope, based on bill purpose)

    • Public awareness and education campaigns about uterine fibroids, their symptoms, risk factors, and when to seek care.
    • Training and support for healthcare providers to improve screening, diagnosis, and timely referral for treatment.
    • Collaboration with healthcare facilities to implement screening protocols or pilot programs.
    • Data collection, surveillance, and reporting to monitor detection and intervention outcomes.
    • Access-enhancing interventions, which may include reducing financial, logistical, or geographic barriers to care.

  • Program Administration

    • DOH would administer the grant program, establish guidelines, grant cycles, and reporting requirements for recipients.
    • Potential prioritization criteria (e.g., underserved communities, racial/ethnic groups disproportionately affected by fibroids) are not specified in the summary but may be contemplated in program rules.

Who Would Be Affected

  • Individuals with Uterine Fibroids
    • Potentially benefits from earlier detection, education, and access to interventions.
  • Healthcare Providers and Facilities
    • May receive training, resources, and support to implement screening and referral pathways.
  • Public Health System and DOH
    • Responsibilities include administering grants, monitoring outcomes, and reporting on program effectiveness.
  • Underserved or High-Risk Populations
    • If grant criteria prioritize equity, communities with higher fibroid burden may receive more targeted support.

Procedural and Timeline Aspects

  • The bill specifies an appropriation of $5 million but does not include detailed timelines within the summary.
  • Typically, further procedural steps would include:
    • Rules and regulations outlining grant eligibility, application processes, scoring, and reporting.
    • Grant cycles (e.g., annual or multi-year) and performance metrics.
    • Sunset or renewal provisions, if applicable, to assess program effectiveness.

Potential Impacts and Considerations

  • Public Health Impact
    • Enhanced early detection and intervention could reduce complications, healthcare costs, and improve quality of life for those affected.
  • Equity Considerations
    • The program could address disparities in fibroid care, particularly among populations with higher prevalence or poorer access to care, if targeted in program guidelines.
  • Implementation Details Needed
    • Specific eligibility criteria for non-governmental organizations or healthcare providers receiving grants.
    • Breakdown of how the $5 million will be allocated (e.g., grants to institutions vs. community organizations, grant sizes, and reporting requirements).

If you would like, I can tailor this summary to a specific audience (general public, policy makers, healthcare professionals) or look for the bill’s full text to extract exact provisions, eligibility criteria, and implementation timelines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.